Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 73Carcinoma, Renal Cell 36Urinary Bladder Neoplasms 25Carcinoma, Transitional Cell 14Neoplasm Metastasis 12Melanoma 12Ovarian Neoplasms 11Lung Neoplasms 11Colorectal Neoplasms 11Clear-cell metastatic renal cell carcinoma 10Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Wilms Tumor 8Ureteral Neoplasms 8Pancreatic Neoplasms 8Carcinoma, Hepatocellular 8Lymphoma, Non-Hodgkin 7Glioma 7Urethral Neoplasms 6Sarcoma 6Neuroblastoma 6Hepatoblastoma 6Uterine Cervical Neoplasms 5Rhabdoid Tumor 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Medulloblastoma 5Histiocytosis, Langerhans-Cell 5Ependymoma 5Central Nervous System Neoplasms 5

Interventions

abiraterone 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligometastatic Prostate Carcinoma × Specimen Handling × Genitourinary × Clear all
NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic

Phase 2 Recruiting
110 enrolled
Genitourinary

Oligometastatic Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡